Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
DISASTERS AVERTED — Near Miss Case Studies
Patient’s Method of Figuring Meal-time Insulin Doesn’t Quite Work
TOP STORIES — Diabetes News and Research
Dulaglutide Provides CVD Protection with or without Metformin
Research Highlights Combination Canagliflozin plus Liraglutide Effects on HBA1c
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study
MOST POPULAR ARTICLES OF THE MONTH
#1 Vitamin D Deficiency Linked to Painful Diabetic Neuropathy
#2 A New Way to Potentiate Beta-Cell Regeneration
#3 Insulin and Glucagon Co-administration – Optimizing Glycemic Control without Risks of Hypoglycemia
Letter from the Editor
When we add medications for our patients, our focus is usually directed by such things as A1C, Time in Range, maximum highs and the like. However, when we add these medications we don’t see a noticeable difference in the aforementioned parameters.
A good example of how adding medications that don’t necessarily affect a specific target works is seen in a new article that David Clarke, PharmD Candidate, University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences, has prepared for us.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
Newsflash: BYDUREON Pen to Be Discontinued
Effective March 2021, AstraZeneca will discontinue distribution of BYDUREON Pen. Patients should be switched to Bydureon BCise.
Coming Oct 6th! Special Report:
The first installment of “The Future of Type 2 Diabetes Management and The Changing Roles of Healthcare Professionals.”
Adherence-related issues are hemorrhaging the costs of diabetes-related treatment in America. To offset this tragedy, GlucosePATH is utilized by a team of healthcare professionals dedicated to improving the quality of life while decreasing avoidable costs. Don’t miss this special feature, exclusively in Diabetes in Control.
DISASTERS AVERTED — Near Miss Case Studies
Recently I assessed an 84-year-old inpatient with diabetes for his insulin usage at home. In reporting his dosing, he stated that after he checked his glucose before each meal, he took the “first two numbers of the result,” and made his dosage for meal-time insulin….
TOP STORIES — Diabetes News and Research
Data from the REWIND trial suggest that dulaglutide has cardioprotective properties.
The combination of an SGLT2i plus a GLP-1 RA results in surprising effects on endogenous glucose production and HBA1c.
Care of the elderly can be very challenging. Can adding yet another medication actually help?